Basic and clinical studies on pazufloxacin in the urological field

Toyohiko Watanabe, T. Takenaka, K. Sakuramoto, T. Hayashi, K. Hata, N. Ono, M. Tsugawa, H. Kumon, H. Ohmori, Y. Nasu, S. Hayata, A. Mizuno, M. Kishi, T. Asahi

Research output: Contribution to journalArticle

Abstract

We studied the antibacterial activity and efficacy of pazufloxacin (PZFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of PZFX were measured against 207 clinical isolates of 14 species from urinary tract infections and compared with those of norfloxacin (NFLX) and ofloxacin (OFLX). In general, the antibacterial activity of PZFX was superior or equal to those of NFLX and OFLX. 2) Statistical studies were performed on Pseudomonas aeruginosa isolated from patients with urinary tract infection from 1983 to 1991. Antibacterial activities of PZFX, NFLX and OFLX against these strains were annually reduced both in Muller-Hinton broth (MHB) and in artificial urine (AU). Antibacterial activities of these new quinolones in AU were more reduced than those in MHB, but the antibacterial activity of PZFX was less reduced in AU than those of NFLX and OFLX in AU. It was considered that the antimicrobial activities of the new quinolones were reduced due to low pH and high concentrations of magnesium and calcium in AU. 3) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 71% (12/17) for chronic complicated UTI. Bacteriologically, 19 of 23 strains (83%) isolated were eradicated. 4) Side effects: No clinical adverse reactions and no abnormal laboratory findings were noted.

Original languageEnglish
Pages (from-to)363-376
Number of pages14
JournalJapanese Journal of Chemotherapy
Volume43
Issue numberSUPPL. 2
Publication statusPublished - 1995

Fingerprint

Norfloxacin
Ofloxacin
Urine
Quinolones
Urinary Tract Infections
Pseudomonas aeruginosa
Magnesium
pazufloxacin
Clinical Studies
Calcium

Keywords

  • PZFX

ASJC Scopus subject areas

  • Pharmacology

Cite this

Watanabe, T., Takenaka, T., Sakuramoto, K., Hayashi, T., Hata, K., Ono, N., ... Asahi, T. (1995). Basic and clinical studies on pazufloxacin in the urological field. Japanese Journal of Chemotherapy, 43(SUPPL. 2), 363-376.

Basic and clinical studies on pazufloxacin in the urological field. / Watanabe, Toyohiko; Takenaka, T.; Sakuramoto, K.; Hayashi, T.; Hata, K.; Ono, N.; Tsugawa, M.; Kumon, H.; Ohmori, H.; Nasu, Y.; Hayata, S.; Mizuno, A.; Kishi, M.; Asahi, T.

In: Japanese Journal of Chemotherapy, Vol. 43, No. SUPPL. 2, 1995, p. 363-376.

Research output: Contribution to journalArticle

Watanabe, T, Takenaka, T, Sakuramoto, K, Hayashi, T, Hata, K, Ono, N, Tsugawa, M, Kumon, H, Ohmori, H, Nasu, Y, Hayata, S, Mizuno, A, Kishi, M & Asahi, T 1995, 'Basic and clinical studies on pazufloxacin in the urological field', Japanese Journal of Chemotherapy, vol. 43, no. SUPPL. 2, pp. 363-376.
Watanabe T, Takenaka T, Sakuramoto K, Hayashi T, Hata K, Ono N et al. Basic and clinical studies on pazufloxacin in the urological field. Japanese Journal of Chemotherapy. 1995;43(SUPPL. 2):363-376.
Watanabe, Toyohiko ; Takenaka, T. ; Sakuramoto, K. ; Hayashi, T. ; Hata, K. ; Ono, N. ; Tsugawa, M. ; Kumon, H. ; Ohmori, H. ; Nasu, Y. ; Hayata, S. ; Mizuno, A. ; Kishi, M. ; Asahi, T. / Basic and clinical studies on pazufloxacin in the urological field. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43, No. SUPPL. 2. pp. 363-376.
@article{e98a9a70f7d048358d7d4912b9669d44,
title = "Basic and clinical studies on pazufloxacin in the urological field",
abstract = "We studied the antibacterial activity and efficacy of pazufloxacin (PZFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of PZFX were measured against 207 clinical isolates of 14 species from urinary tract infections and compared with those of norfloxacin (NFLX) and ofloxacin (OFLX). In general, the antibacterial activity of PZFX was superior or equal to those of NFLX and OFLX. 2) Statistical studies were performed on Pseudomonas aeruginosa isolated from patients with urinary tract infection from 1983 to 1991. Antibacterial activities of PZFX, NFLX and OFLX against these strains were annually reduced both in Muller-Hinton broth (MHB) and in artificial urine (AU). Antibacterial activities of these new quinolones in AU were more reduced than those in MHB, but the antibacterial activity of PZFX was less reduced in AU than those of NFLX and OFLX in AU. It was considered that the antimicrobial activities of the new quinolones were reduced due to low pH and high concentrations of magnesium and calcium in AU. 3) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 71{\%} (12/17) for chronic complicated UTI. Bacteriologically, 19 of 23 strains (83{\%}) isolated were eradicated. 4) Side effects: No clinical adverse reactions and no abnormal laboratory findings were noted.",
keywords = "PZFX",
author = "Toyohiko Watanabe and T. Takenaka and K. Sakuramoto and T. Hayashi and K. Hata and N. Ono and M. Tsugawa and H. Kumon and H. Ohmori and Y. Nasu and S. Hayata and A. Mizuno and M. Kishi and T. Asahi",
year = "1995",
language = "English",
volume = "43",
pages = "363--376",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Basic and clinical studies on pazufloxacin in the urological field

AU - Watanabe, Toyohiko

AU - Takenaka, T.

AU - Sakuramoto, K.

AU - Hayashi, T.

AU - Hata, K.

AU - Ono, N.

AU - Tsugawa, M.

AU - Kumon, H.

AU - Ohmori, H.

AU - Nasu, Y.

AU - Hayata, S.

AU - Mizuno, A.

AU - Kishi, M.

AU - Asahi, T.

PY - 1995

Y1 - 1995

N2 - We studied the antibacterial activity and efficacy of pazufloxacin (PZFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of PZFX were measured against 207 clinical isolates of 14 species from urinary tract infections and compared with those of norfloxacin (NFLX) and ofloxacin (OFLX). In general, the antibacterial activity of PZFX was superior or equal to those of NFLX and OFLX. 2) Statistical studies were performed on Pseudomonas aeruginosa isolated from patients with urinary tract infection from 1983 to 1991. Antibacterial activities of PZFX, NFLX and OFLX against these strains were annually reduced both in Muller-Hinton broth (MHB) and in artificial urine (AU). Antibacterial activities of these new quinolones in AU were more reduced than those in MHB, but the antibacterial activity of PZFX was less reduced in AU than those of NFLX and OFLX in AU. It was considered that the antimicrobial activities of the new quinolones were reduced due to low pH and high concentrations of magnesium and calcium in AU. 3) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 71% (12/17) for chronic complicated UTI. Bacteriologically, 19 of 23 strains (83%) isolated were eradicated. 4) Side effects: No clinical adverse reactions and no abnormal laboratory findings were noted.

AB - We studied the antibacterial activity and efficacy of pazufloxacin (PZFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of PZFX were measured against 207 clinical isolates of 14 species from urinary tract infections and compared with those of norfloxacin (NFLX) and ofloxacin (OFLX). In general, the antibacterial activity of PZFX was superior or equal to those of NFLX and OFLX. 2) Statistical studies were performed on Pseudomonas aeruginosa isolated from patients with urinary tract infection from 1983 to 1991. Antibacterial activities of PZFX, NFLX and OFLX against these strains were annually reduced both in Muller-Hinton broth (MHB) and in artificial urine (AU). Antibacterial activities of these new quinolones in AU were more reduced than those in MHB, but the antibacterial activity of PZFX was less reduced in AU than those of NFLX and OFLX in AU. It was considered that the antimicrobial activities of the new quinolones were reduced due to low pH and high concentrations of magnesium and calcium in AU. 3) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 71% (12/17) for chronic complicated UTI. Bacteriologically, 19 of 23 strains (83%) isolated were eradicated. 4) Side effects: No clinical adverse reactions and no abnormal laboratory findings were noted.

KW - PZFX

UR - http://www.scopus.com/inward/record.url?scp=0028793973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028793973&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028793973

VL - 43

SP - 363

EP - 376

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 2

ER -